EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering

Cristina Espadas, Manuel Soto-Catalán, María Romero-Cote iD, María Kavanagh, Isabel Herrero-Del Real iD, Adriana Ortega-Hernández iD, Jairo Lumpuy-Castillo iD, Dulcenombre Gómez-Garre iD, Jesús Egido iD, José Tuñón iD, Carmen Gómez-Guerrero iD, Óscar Lorenzo iD

Biomolecules · 06.03.2026 · 16 (3) · 397

DOI: 10.3390/biom16030397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 06.03.2026. Verfasst von Cristina Espadas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Vascular Pathology and Diabetes, Fundación Instituto de Investigaciones Sanitarias-Fundación Jiménez Díaz, Universidad Autónoma, 28040 …. Hauptthemen laut MEDLINE: Macrophages, Proprotein Convertase 9, Antibodies, Monoclonal, Humanized, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has been implicated in vascular inflammation beyond its action on LDL-C degradation. We investigated whether PCSK9 may exacerbate proinflammatory signaling of M1 macrophages and if its neutralization with alirocumab could attenuate this effect and plaque progression by LDL-C independent mechanisms.

Methods

ApoE−/− mice were treated with alirocumab for 13 weeks, and aortic arches were isolated for atherosclerotic plaque characterization based on lesion size and lipid and macrophage infiltration. Plasma and splenic monocytes/macrophages were also assessed by flow cytometry, and PCSK9, the lipid profile, and inflammatory cytokines were measured by qPCR or Western blot. Cultured THP-1-derived M1 macrophages were stimulated with PCSK9 and evaluated for TLR4-NFκB-NLRP3 activation and cytokine production. In addition, soluble PCSK9, LDL-C, and proinflammatory factors were analyzed in 1190 patients with acute coronary syndrome (ACS).

Results

Alirocumab reduced plaque lesion (0.42-fold; p < 0.05) and lipid (0.63-fold; p < 0.01) and macrophage (0.61-fold; p < 0.05) infiltration, mainly the M1 subtype (0.37-fold; p < 0.01), as well as TLR4, NLRP3 and caspase-1 expressions (0.49-fold, 0.51-fold and 0.51-fold, respectively; p < 0.05), without altering LDL-C. Also, it decreased proinflammatory cytokines but enhanced anti-inflammatory factors and M2 markers at the descending aorta. Alirocumab enriched circulating Ly6Clow monocytes (1.51-fold; p < 0.05) and splenic M2 macrophages (1.32-fold; p < 0.01), while reducing M1 (0.62-fold; p < 0.05). In cultured M1 macrophages, PCSK9 overexpressed proinflammatory cytokines (i.e., CXCL9, CXCL10, TNF-α, IL-1β, and IL-6), downregulated anti-inflammatory mediators (i.e., CCL17, TGM2, TGF-β1, and IL-10), and promoted NFκB-p65 nuclear translocation and NLRP3 and gasdermin-D activation. However, TLR4 inhibition or silencing blunted these effects. In patients with AC, there was a positive association between PCSK9 and hsCRP and FGF-23 plasma levels, independently of LDL-C.

Conclusions

PCSK9 may be released in parallel to proinflammatory factors such as hsCRP and FGF-23 in patients with ACS, independently of LDL-C levels. PCSK9 may directly promote macrophage-driven inflammatory responses through the TLR4-NFκB-NLRP3 signaling, but its neutralization with alirocumab attenuated this inflammatory axis and limited atherosclerotic progression, supporting an anti-inflammatory benefit secondary to PCSK9 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesProprotein Convertase 9Antibodies, Monoclonal, HumanizedInflammationPlaque, AtheroscleroticAnimalsHumansMiceSignal TransductionMaleToll-Like Receptor 4FemaleMice, KnockoutCytokines

Stichwörter der Autor:innen

NFκBNLRP3PCSK9alirocumabinflammation

Substanzen

alirocumabProprotein Convertase 9Antibodies, Monoclonal, HumanizedToll-Like Receptor 4PCSK9 protein, humanCytokinesPcsk9 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Vascular Pathology and Diabetes, Fundación Instituto de Investigaciones Sanitarias-Fundación Jiménez Díaz, Universidad Autónoma, 28040 Madrid, Spain.
  • Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, 28029 Madrid, Spain.
  • Laboratory of Vascular Biology and Microbiota, Instituto de Investigaciones Sanitarias Hospital Clínico San Carlos, 28040 Madrid, Spain.
  • Department of Cardiology, Hospital Fundación Jiménez Díaz, Universidad Autónoma, 28040 Madrid, Spain.
  • Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV) Network, 28029 Madrid, Spain.

ORCID-Profile: María Romero-Cote, Isabel Herrero-Del Real, Adriana Ortega-Hernández, Jairo Lumpuy-Castillo, Dulcenombre Gómez-Garre, Jesús Egido, José Tuñón, Carmen Gómez-Guerrero, Óscar Lorenzo

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Espadas, C., Soto-Catalán, M., Romero-Cote, M., Kavanagh, M., Herrero-Del Real, I., Ortega-Hernández, A., Lumpuy-Castillo, J., Gómez-Garre, D., Egido, J., Tuñón, J., Gómez-Guerrero, C., & Lorenzo, Ó. (2026). Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering. Biomolecules, 16(3), 397. https://doi.org/10.3390/biom16030397

Vancouver

Espadas C, Soto-Catalán M, Romero-Cote M, Kavanagh M, Herrero-Del Real I, Ortega-Hernández A, et al. Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering. Biomolecules. 2026;16(3):397. doi:10.3390/biom16030397

BibTeX
@article{Espadas2026,
  author = {Espadas, Cristina and Soto-Catalán, Manuel and Romero-Cote, María and Kavanagh, María and Herrero-Del Real, Isabel and Ortega-Hernández, Adriana and Lumpuy-Castillo, Jairo and Gómez-Garre, Dulcenombre and Egido, Jesús and Tuñón, José and Gómez-Guerrero, Carmen and Lorenzo, Óscar},
  title = {Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {397},
  doi = {10.3390/biom16030397}
}
Kostenlos starten →